SP
BravenNow
Exelixis director Wyszomierski sells $4.38 million in stock
| USA | economy | ✓ Verified - investing.com

Exelixis director Wyszomierski sells $4.38 million in stock

#Exelixis #Wyszomierski #Insider Trading #Stock Sales #Biotech #Earnings Beat #Cancer Drug #Market Capitalization

📌 Key Takeaways

  • Exelixis director sold $4.38 million worth of company stock on February 18, 2026
  • Transactions were executed under a pre-planned trading rule adopted in November 2025
  • Company reported earnings beat of 21.25% but missed revenue expectations
  • Analysts remain optimistic about Exelixis's cancer drug pipeline and future prospects

📖 Full Retelling

Exelixis director Jack L. Wyszomierski sold 99,574 shares of common stock on February 18, 2026, for approximately $4.38 million in transactions executed at prices ranging from $43.32 to $44.49 per share. The biotechnology company, which trades on NASDAQ under the symbol EXEL, has a market capitalization of $11.3 billion and currently operates with a price-to-earnings ratio of 15.7. According to regulatory filings, the sales were conducted pursuant to a Rule 10b5-1 trading plan that Wyszomierski adopted on November 19, 2025, suggesting the transactions were pre-planned and not based on inside information. On the same day as the sales, the director also exercised options to acquire 20,634 shares of Exelixis common stock at a price of $19.77, totaling approximately $407,934. Following these transactions, Wyszomierski directly owns 279,942 shares of Exelixis, including 9,812 shares that will be issued upon the vesting of restricted stock units. The company has demonstrated strong financial performance with a return on equity of 36% over the past twelve months, indicating efficient capital management and profitability. Recent earnings results showed Exelixis beat analyst expectations with earnings per share of $0.97, surpassing the forecast of $0.80, though revenue came in slightly below expectations at $598.66 million compared to the anticipated $604.56 million. Analyst firms have responded positively to the company's prospects, with H.C. Wainwright raising its price target from $52 to $54 while maintaining a Buy rating, and Citizens reaffirming its Market Outperform rating with a $50 price target, citing optimism around Exelixis's cancer drug zanzalintinib and its potential for treating metastatic colorectal cancer.

🏷️ Themes

Executive Trading, Biopharmaceutical Performance, Market Analysis

📚 Related People & Topics

Insider trading

Insider trading

Trading using nonpublic information

# Insider Trading **Insider trading** is the trading of a public company's stock or other securities (such as bonds or stock options) based on **material, nonpublic information** about the company. While the practice is common, its legality is subject to complex regulations that vary significantly ...

View Profile → Wikipedia ↗
Biotechnology

Biotechnology

Use of living systems and organisms to develop or make useful products

Biotechnology is a multidisciplinary field that involves the integration of natural sciences and engineering sciences in order to achieve the application of organisms and parts thereof for products and services. Specialists in the field are known as biotechnologists. The term biotechnology was first...

View Profile → Wikipedia ↗

Exelixis

American biotechnology company

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

View Profile → Wikipedia ↗

Entity Intersection Graph

Connections for Insider trading:

🌐 SEC filing 5 shared
👤 New York Stock Exchange 4 shared
👤 Rachel Haurwitz 3 shared
🌐 ZWS 2 shared
🌐 Biopharmaceutical 2 shared
View full profile

Deep Analysis

Why It Matters

The sale of $4.38 million in Exelixis stock by its director signals confidence in the company’s prospects and may influence investor sentiment. It also highlights the use of a Rule 10b5-1 plan, which is a common mechanism for insiders to manage trades.

Context & Background

  • Exelixis is a biotech firm focused on cancer therapies
  • The director sold 99,574 shares and exercised options for 20,634 shares
  • The company reported a Q4 2025 earnings beat but revenue fell short
  • The stock trades at a P/E of 15.7, below its fair value estimate
  • The director’s net holdings after the sale are 279,942 shares

What Happens Next

Investors may monitor the company’s upcoming drug development pipeline and regulatory approvals. Market analysts will likely reassess valuation metrics following the insider sale and earnings results.

Frequently Asked Questions

What is a Rule 10b5-1 trading plan?

It is a prearranged strategy that allows insiders to sell shares at predetermined times and prices, reducing the risk of insider trading allegations.

How does the insider sale affect Exelixis stock?

While insider sales can signal confidence, they may also trigger short-term volatility; investors should consider the overall financial performance.

What are the implications of the earnings beat?

The earnings beat suggests strong profitability, but the revenue miss indicates potential challenges in sales growth.

What is zanzalintinib?

It is a cancer drug under development by Exelixis aimed at treating metastatic colorectal cancer.

Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Trump imposes new 10% global levy as SCOTUS strikes down sweeping tariffs Gold rises, silver jumps after disappointing economic data, SCOTUS tariff ruling Stocks end higher after SCOTUS tariff ruling, S&P 500 snaps two-week losing streak U.S. military operation in Iran "likely at this stage," Raymond James says (South Africa Philippines Nigeria) Exelixis director Wyszomierski sells $4.38 million in stock By Investing.com Insider Trading Published 02/20/2026, 08:46 PM Exelixis director Wyszomierski sells $4.38 million in stock 0 EXEL -1.20% Director Jack L. Wyszomierski of Exelixis, Inc. (NASDAQ:EXEL) sold 99,574 shares of common stock on February 18, 2026, for approximately $4.38 million. The sales were executed at prices ranging from $43.32 to $44.49. The biotech company, with a market capitalization of $11.3 billion, currently trades at a P/E ratio of 15.7, which InvestingPro data suggests is undervalued relative to its Fair Value estimate. On the same day, Wyszomierski also exercised options to acquire 20,634 shares of Exelixis common stock at a price of $19.77, totaling $407934. Following these transactions, Wyszomierski directly owns 279,942 shares of Exelixis, Inc., including 9,812 shares of common stock that will be issued upon the vesting of restricted stock units. According to InvestingPro Tips, the company has been profitable over the last twelve months with a strong return on equity of 36%. Investors seeking deeper insights can access the comprehensive Pro Research Report, available for EXEL and 1,400+ other US equities. The sales were conducted under a Rule 10b5-1 trading plan adopted on November 19, 2025. In other recent news, Exelixis reported its fourth-quarter 2025 earnings, showcasing a notable earnings per share beat. The company posted an EPS of $0.97, surpassing the forecast of $0.80, marking a 21.25% increase. However, the revenue figures did not meet expectations, coming in at $598.66 mi...
Read full article at source

Source

investing.com

More from USA

News from Other Countries

🇬🇧 United Kingdom

🇺🇦 Ukraine